Peter Perdik, MD
Internal Medicine · New Hyde Park, NYNPI 1760429294
Payments from drug & device makers
Across 347 payments — averaging $28.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- Amgen$554
- Genentech USA, Inc.$462
- Welch Allyn$356
- plus $2K from 24 others
What the payments were for
- Food & beverage$9,52195%
- Education$1411%
- Gifts$3564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 105 | $2,738 |
| AstraZeneca | 46 | $2,359 |
| Boehringer Ingelheim | 80 | $1,760 |
| Amgen | 11 | $554 |
| Genentech USA, Inc. | 13 | $462 |
| Welch Allyn | 1 | $356 |
| Pfizer | 7 | $233 |
| Kowa Pharmaceuticals America, Inc. | 15 | $190 |
| Novartis | 10 | $186 |
| Regeneron Healthcare Solutions, Inc. | 7 | $138 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Philips North America LLC | 5 | $89 |
| AbbVie(2 entities) | 4 | $83 |
| Novo Nordisk | 4 | $76 |
| Merck | 4 | $73 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Daiichi Sankyo Inc. | 3 | $66 |
| Mallinckrodt Hospital Products Inc. | 2 | $65 |
| Sanofi | 3 | $63 |
| Sunovion Pharmaceuticals Inc. | 7 | $62 |
| Jazz Pharmaceuticals Inc. | 3 | $57 |
| Lilly USA, LLC | 3 | $46 |
| Johnson & Johnson | 2 | $40 |
| Nevro Corp. | 1 | $33 |
| Insmed, Inc. | 1 | $32 |
| Althera Pharmaceuticals LLC | 1 | $24 |
| Abbott | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$1,114
- AIRSUPRA$471
- Repatha$248
- ANORO ELLIPTA$238
- TRELEGY ELLIPTA$234
- FASENRA$125
- Otezla$123
- NUCALA$120
- ELIQUIS$118
- AREXVY$118
How this compares
$10,018 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 278 | $316,648 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $87,184 |
| EliquisApixaban | 55 | $63,836 |
| Dupixent PenDupilumab | 13 | $48,453 |
| OzempicSemaglutide | 20 | $42,940 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $34,506 |
| XareltoRivaroxaban | 18 | $28,114 |
| Spiriva RespimatTiotropium Bromide | 35 | $27,814 |
| JardianceEmpagliflozin | 15 | $25,570 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 524 | $21,046 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $14,860 |
| JanuviaSitagliptin Phosphate | 11 | $13,496 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $11,741 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $9,918 |
| Wixela InhubFluticasone Propion/Salmeterol | 42 | $8,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,738 | $375,415367 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,359 | $94,73397 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance, Stiolto Respimat | $1,760 | $68,24571 claims |
| PfizerEliquis | $233 | $63,83655 claims |
| Novo NordiskOzempic | $76 | $42,94020 claims |
| Johnson & JohnsonXarelto | $40 | $28,11418 claims |
| MerckJanuvia, Janumet | $73 | $20,99224 claims |
| AbbVieSynthroid | $83 | $1,88418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New Hyde Park
- Nagashree SeetharamuNew Hyde Park$2.5M
- Janice WangNew Hyde Park$2.1M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.